Clinical trials: Moderate COPD
Chronic Obstructive Pulmonary Disease
Glasgow Supported Self Management Trial (GSuST)
Training patients to alter their own therapy early in the course of a developing exacerbation (self-management) has been shown to improve outcomes in asthma, but there is no good evidence on this for patients with Chronic…
- Trial name
- GSuST (NCT00706303)
- Testing
- Supported self management training and support
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- NHS Greater Glasgow and Clyde
Chronic Obstructive Pulmonary Disease
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary…
- Trial name
- BEACON (NCT01529632)
- Testing
- QVA149, NVA237, QAB149
- Where
- 26 sites in Austria, Denmark and 3 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation
- Trial name
- NCT01834885
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 29 sites in Austria, Germany
- Sponsor
- Novartis Pharmaceuticals
COPD, Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of…
- Trial name
- NCT00380796
- Testing
- Collection of safety data for Cohort 1
- Where
- 26 sites in United States
- Volunteers
- 88 people
- Sponsor
- Centocor, Inc.
COPD
Continuous Versus High Intensity Interval Exercise in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is characterized by exercise intolerance, which is a prognostic factor of disease severity and mortality and is usually attributed to ventilatory limitations.
- Trial name
- NCT07707271
- Testing
- Moderate intensity continuous aerobic exercise (MICE), High-intensity interval aerobic exercise (HIIE)
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- George Papanicolaou Hospital
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.
- Trial name
- NCT01860066
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 31 sites in Argentina, Belgium and 3 more
- Sponsor
- Novartis Pharmaceuticals
Asthma Copd
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary…
- Trial name
- ESPIRE (NCT04233190)
- Testing
- Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
- Where
- Brazil
- Volunteers
- 472 people
- Sponsor
- Eurofarma Laboratorios S.A.
Chronic Obstructive Pulmonary Disease
A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD
The effectiveness of clinic-based pulmonary rehabilitation in advanced Chronic Obstructive Pulmonary Disease (COPD) is well established, but few data exist for less severe patients treated in alternative settings.
- Trial name
- NCT01985529
- Testing
- Exercise
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Los Angeles